🇺🇸 FDA
Patent

US 7097965

Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein

granted A61KA61K39/00

Quick answer

US patent 7097965 (Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Aug 24 2026 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Aug 29 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 24 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K39/00